Hannaman Mary R, Fitts Douglas A, Doss Rose M, Weinstein David E, Bryant Joseph L
NeuroDigm Corporation, Colorado Springs, CO, 80906, USA.
Department of Integrative Physiology, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA.
F1000Res. 2016 Oct 13;5:2516. doi: 10.12688/f1000research.9544.2. eCollection 2016.
Many humans suffering with chronic neuropathic pain have no objective evidence of an etiological lesion or disease. Frequently their persistent pain occurs after the healing of a soft tissue injury. Based on clinical observations over time, our hypothesis was that after an injury in mammals the process of tissue repair could cause chronic neural pain. Our objectives were to create the delayed onset of neuropathic pain in rats with minimal nerve trauma using a physiologic hydrogel, and characterize the rats' responses to known analgesics and a targeted biologic. In mature male Sprague Dawley rats (age 9.5 months) a percutaneous implant of tissue-derived hydrogel was placed in the musculofascial tunnel of the distal tibial nerve. Subcutaneous morphine (3 mg/kg), celecoxib (10 mg/kg), gabapentin (25 mg/kg) and duloxetine (10 mg/kg) were each screened in the model three times each over 5 months after pain behaviors developed. Sham and control groups were used in all screenings. A pilot study followed in which recombinant human erythropoietin (200 units) was injected by the GEL™ neural procedure site. The GEL group gradually developed mechanical hypersensitivity lasting months. Morphine, initially effective, had less analgesia over time. Celecoxib produced no analgesia, while gabapentin and duloxetine at low doses demonstrated profound analgesia at all times tested. The injected erythropoietin markedly decreased bilateral pain behavior that had been present for over 4 months, ≤ 0.001. Histology of the GEL group tibial nerve revealed a site of focal neural remodeling, with neural regeneration, as found in nerve biopsies of patients with neuropathic pain. The refined NeuroDigm GEL™ model induces a neural response resulting in robust neuropathic pain behavior. The analgesic responses in this model reflect known responses of humans with neuropathic pain. The targeted recombinant human erythropoietin at the ectopic neural lesion appears to alleviate the persistent pain behavior in the GEL™ model rodents.
许多患有慢性神经性疼痛的人并没有病因性损伤或疾病的客观证据。他们的持续性疼痛常常在软组织损伤愈合后出现。基于长期的临床观察,我们的假设是,在哺乳动物受伤后,组织修复过程可能会导致慢性神经疼痛。我们的目标是使用生理性水凝胶,以最小的神经创伤在大鼠中引发迟发性神经性疼痛,并描述大鼠对已知镇痛药和一种靶向生物制剂的反应。在成年雄性斯普拉格-道利大鼠(9.5个月龄)中,将组织源性水凝胶经皮植入胫神经远端的肌筋膜隧道。在疼痛行为出现后的5个月内,对皮下注射吗啡(3毫克/千克)、塞来昔布(10毫克/千克)、加巴喷丁(25毫克/千克)和度洛西汀(10毫克/千克)分别进行了三次筛选。所有筛选均使用假手术组和对照组。随后进行了一项初步研究,通过GEL™神经手术部位注射重组人促红细胞生成素(200单位)。GEL组逐渐出现持续数月的机械性超敏反应。吗啡最初有效,但随着时间的推移镇痛效果减弱。塞来昔布没有产生镇痛作用,而低剂量的加巴喷丁和度洛西汀在所有测试时间都表现出显著的镇痛作用。注射促红细胞生成素显著降低了持续超过4个月的双侧疼痛行为,P≤0.001。GEL组胫神经的组织学检查显示有一个局灶性神经重塑部位,伴有神经再生,这与神经性疼痛患者的神经活检结果一致。改良后的NeuroDigm GEL™模型可诱导神经反应并导致强烈的神经性疼痛行为。该模型中的镇痛反应反映了神经性疼痛患者的已知反应。在异位神经损伤部位注射靶向重组人促红细胞生成素似乎可以减轻GEL™模型啮齿动物的持续性疼痛行为。